Download - Bayer HealthCare

Key fi gures 2012
Bayer HealthCare 2011 2012 Change
€ million % Fx(& p) adj. %
Sales 17,169 18,612 8.4 4.2
EBITDA 4,502 3,815 -15.3
Special items ­200 ­1,253
EBIT 3,191 2,154 -32.5
Special items ­176 ­1,582
Gross cash fl ow 3,254 2,614 -19.7
net cash fl ow 3,357 3,543 5.5
Sales by division 2011 2012 Change
€ million % Fx(& p) adj. %
Animal Health 1,186 1,303 9.9 4.2
Consumer Care 3,534 3,853 9.0 5.6
Medical Care 2,500 2,653 6.1 2.2
Pharmaceuticals 9,949 10,803 8.6 4.2
Sales by region 2011 2012 Change
€ million % Fx adj. %
Europe 6,376 6,484 1.7 0.9
north America 4,360 4,961 13.8 5.5
Asia/Pacifi c 3,656 4,203 15.0 6.2
Latin America/Africa/Middle East 2,777 2,964 6.7 5.6
Best-Selling Pharmaceuticals Products 2011 2012 Change
€ million % Fx adj. %
Betaferon/Betaseron 1,117 1,216 8.9 4.2
Kogenate 1,075 1,182 10.0 5.2
YAZ/Yasmin/Yasminelle 1,070 1,045 -2.3 -5.0
Nexavar 725 792 9.2 4.2
Mirena 581 677 16.5 9.4
Adalat 640 670 4.7 -2.3
Avalox/Avelox 486 486 0.0 -5.0
Aspirin Cardio 404 476 17.8 12.3
Glucobay 362 408 12.7 3.6
Xarelto 86 322 274.4 265.9
Levitra 332 307 -7.5 -9.1
Cipro/Ciprobay 232 229 -1.3 -5.1
Zetia 179 207 15.6 7.5
Diane 182 194 6.6 4.9
Fosrenol 147 187 27.2 18.0
Total 7,618 8,398 10.2 5.2
Proportion of Pharmaceuticals sales 77 % 78 %
Best-Selling Consumer Health Products 2011 2012 Change
€ million % Fx adj. %
Contour (Medical Care) 640 722 12.8 8.5
Advantage product line (Animal Health) 420 495 17.9 10.6
Aspirin* (Consumer Care) 471 494 4.9 1.3
Ultravist (Medical Care) 316 324 2.5 -1.5
Aleve/naproxen (Consumer Care) 285 323 13.3 5.4
Bepanthen/Bepanthol (Consumer Care) 235 269 14.5 13.9
Canesten (Consumer Care) 224 250 11.6 7.8
Gadovist/Gadavist (Medical Care) 160 209 30.6 27.2
One A Day (Consumer Care) 174 196 12.6 4.0
Iopamiron (Medical Care) 185 174 -5.9 -12.3
Total 3,110 3,456 11.1 6.2
Proportion of Consumer Health sales 43 % 44 % Fx (& p) adj. = currency- (and portfolio-)adjusted | Fx adj. = currency-adjusted
* Sales of Aspirin (including Aspirin Complex) – including Aspirin Cardio, which is refl ected in sales of the
Pharmaceuticals segment – increased by 10.9% (Fx adj. +6.4%) in 2012 to €970 million (2011: €875 million).